Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54,711,345
-
Total 13F shares
-
38,384,996
-
Share change
-
+4,019,561
-
Total reported value
-
$2,377,144,958
-
Put/Call ratio
-
11%
-
Price per share
-
$61.93
-
Number of holders
-
90
-
Value change
-
+$253,209,485
-
Number of buys
-
46
-
Number of sells
-
34
Institutional Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q4 2020
As of 31 Dec 2020,
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) was held by
90 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,384,996 shares.
The largest 10 holders included
ATP Life Science Ventures, L.P., FMR LLC, RTW INVESTMENTS, LP, Redmile Group, LLC, BlackRock Inc., VANGUARD GROUP INC, GILDER GAGNON HOWE & CO LLC, Cormorant Asset Management, LP, FEDERATED HERMES, INC., and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
91
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.